Equities analysts forecast that Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will announce earnings of $0.05 per share for the current fiscal quarter, Zacks reports. Nine analysts have provided estimates for Vertex Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.05) and the highest is $0.10. Vertex Pharmaceuticals reported earnings of ($0.01) per share in the same quarter last year, which indicates a positive year over year growth rate of 600%. The company is scheduled to report its next quarterly earnings report on Wednesday, July 26th.

According to Zacks, analysts expect that Vertex Pharmaceuticals will report full-year earnings of $0.43 per share for the current fiscal year, with EPS estimates ranging from $0.15 to $0.63. For the next year, analysts anticipate that the company will post earnings of $1.28 per share, with EPS estimates ranging from $0.90 to $1.82. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Vertex Pharmaceuticals.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Thursday, April 27th. The pharmaceutical company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.09. The company had revenue of $714.72 million for the quarter, compared to analyst estimates of $692.64 million. Vertex Pharmaceuticals had a return on equity of 3.00% and a net margin of 8.64%. The company’s quarterly revenue was up 79.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.09 earnings per share.

VRTX has been the topic of several recent research reports. JMP Securities raised shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their price target for the company from $103.73 to $115.00 in a research report on Friday, March 17th. Vetr cut shares of Vertex Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $102.58 price target on the stock. in a research report on Thursday, April 20th. Zacks Investment Research cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, April 10th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $126.00 price target on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 2nd. Finally, Citigroup Inc. raised their price target on shares of Vertex Pharmaceuticals from $105.00 to $124.00 and gave the company a “buy” rating in a research report on Wednesday, March 29th. Nine analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $117.02.

COPYRIGHT VIOLATION WARNING: “Vertex Pharmaceuticals Incorporated (VRTX) Expected to Post Earnings of $0.05 Per Share” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/06/19/vertex-pharmaceuticals-incorporated-vrtx-expected-to-post-earnings-of-0-05-per-share.html.

In other Vertex Pharmaceuticals news, CEO Jeffrey M. Leiden sold 157,200 shares of the business’s stock in a transaction on Friday, April 28th. The shares were sold at an average price of $119.50, for a total value of $18,785,400.00. Following the completion of the sale, the chief executive officer now directly owns 395,152 shares of the company’s stock, valued at $47,220,664. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Stuart A. Arbuckle sold 70,969 shares of the business’s stock in a transaction on Friday, June 2nd. The stock was sold at an average price of $128.06, for a total transaction of $9,088,290.14. Following the completion of the sale, the executive vice president now directly owns 145,061 shares of the company’s stock, valued at $18,576,511.66. The disclosure for this sale can be found here. Insiders have sold a total of 499,175 shares of company stock valued at $60,610,079 over the last ninety days. 1.90% of the stock is currently owned by insiders.

A number of hedge funds have recently bought and sold shares of the company. BlackRock Inc. increased its stake in Vertex Pharmaceuticals by 2,699.4% in the first quarter. BlackRock Inc. now owns 19,246,380 shares of the pharmaceutical company’s stock valued at $2,104,591,000 after buying an additional 18,558,874 shares in the last quarter. Vanguard Group Inc. increased its stake in Vertex Pharmaceuticals by 3.5% in the first quarter. Vanguard Group Inc. now owns 16,474,890 shares of the pharmaceutical company’s stock valued at $1,801,530,000 after buying an additional 560,796 shares in the last quarter. State Street Corp increased its stake in Vertex Pharmaceuticals by 2.0% in the first quarter. State Street Corp now owns 12,013,178 shares of the pharmaceutical company’s stock valued at $1,313,647,000 after buying an additional 239,017 shares in the last quarter. Clearbridge Investments LLC increased its stake in Vertex Pharmaceuticals by 1.2% in the first quarter. Clearbridge Investments LLC now owns 8,754,618 shares of the pharmaceutical company’s stock valued at $957,317,000 after buying an additional 105,260 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Vertex Pharmaceuticals by 8.9% in the first quarter. Geode Capital Management LLC now owns 2,339,821 shares of the pharmaceutical company’s stock valued at $255,483,000 after buying an additional 191,154 shares in the last quarter. 94.18% of the stock is owned by institutional investors and hedge funds.

Vertex Pharmaceuticals (NASDAQ VRTX) traded up 2.26% during mid-day trading on Monday, reaching $125.92. The company had a trading volume of 864,481 shares. The stock has a 50 day moving average price of $120.30 and a 200 day moving average price of $97.79. Vertex Pharmaceuticals has a one year low of $71.46 and a one year high of $130.69. The company has a market capitalization of $31.36 billion, a P/E ratio of 175.62 and a beta of 1.65.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Get a free copy of the Zacks research report on Vertex Pharmaceuticals (VRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.